Compare PFBC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFBC | DRTS |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | Israel |
| Employees | 324 | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | PFBC | DRTS |
|---|---|---|
| Price | $107.70 | $14.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $102.67 | $8.67 |
| AVG Volume (30 Days) | 94.8K | ★ 569.0K |
| Earning Date | 04-22-2026 | 05-18-2026 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.94 | N/A |
| Revenue Next Year | $8.31 | $699.98 |
| P/E Ratio | $8.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $81.50 | $3.01 |
| 52 Week High | $112.26 | $14.75 |
| Indicator | PFBC | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 60.00 | 61.69 |
| Support Level | $99.20 | $6.59 |
| Resistance Level | $109.99 | N/A |
| Average True Range (ATR) | 2.15 | 0.72 |
| MACD | 0.10 | 0.14 |
| Stochastic Oscillator | 87.30 | 84.43 |
Preferred Bank is a commercial bank located in California. Its products and services are divided into Personal Banking, Business Banking, and Commercial Banking, which include Checking accounts, Savings accounts, CDs, Loans and Credit, Electronic banking, and Treasury Management. It provides personalized deposit services, real estate finance, commercial loans, and trade finance credit facilities to small and mid-sized businesses and their owners, entrepreneurs, real estate developers and investors, professionals, and high-net-worth individuals.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.